Altasciences Doubles Square Footage of their CDMO Facility
Laval, Quebec, March 9, 2021 – Altasciences, a fully integrated early phase CRO/CDMO has started the expansion of their CDMO facility in Philadelphia, PA. The additional 35,000-square-foot building directly adjoins the current location, and will be fully renovated to meet the growing business needs. Phase 1 construction, including warehouse and cGMP manufacturing suites, is expected to be completed by the end of 2021.
The new space, with its 24-foot ceilings, will be configured to include a ~8,750-square-foot warehouse, a ~8,750-square-foot Grade C/D manufacturing area, and a 17,500-square-foot client-dedicated cGMP manufacturing area.
“This expansion ensures that we are in an excellent position to continue to meet the needs of our clients and remain at the forefront of pharmaceutical manufacturing technology. We look forward to seeing this ambitious project come to completion in the coming months,” says Ben Reed, Vice President, Manufacturing, at Altasciences.
Altasciences acquired the Philadelphia CDMO facility in February of 2020, and purchased the new building in December of 2020.
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.